NASDAQ: ASMBAssembly Biosciences Inc Stock
$22.53+0.27 (+1.21%)
Updated Jun 11, 2026
ASMB Price
$22.53
Fair Value Price
N/A
Market Cap
$358.06M
52 Week Low
$15.84
52 Week High
$39.71
P/E
-204.82x
P/B
1.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.38M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.19
Operating Cash Flow
-$40M
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ASMB Overview
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ASMB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ASMB
Ranked#81 of 463
Ranked#81 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important ASMB news, forecast changes, insider trades & much more!
ASMB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ASMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASMB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ASMB is good value based on its book value relative to its share price (1.8x), compared to the US Biotechnology industry average (4.83x)
P/B vs Industry Valuation
ASMB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ASMB due diligence checks available for Premium users.
Valuation
ASMB fair value
Fair Value of ASMB stock based on Discounted Cash Flow (DCF)
Price
$22.53
Fair Value
$4.98
Overvalued by
352.48%
ASMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ASMB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-204.82x
Industry
17.66x
Market
13.95x
ASMB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.8x
Industry
4.83x
ASMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ASMB's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.1M
Profit Margin
0%
ASMB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$235.5M
Liabilities
$36.9M
Debt to equity
0.19
ASMB's short-term assets ($232.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASMB's short-term assets ($232.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASMB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ASMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.1M
Investing
-$5.4M
Financing
$149.0k
ASMB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ASMB vs Biotech Stocks
Assembly Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.